Type of publications
Topics
Diseases
Publication date

Purpose, structure and functioning of the SAGE Working Groups

Download:
Published: 2020

Pneumococcal conjugate vaccines in infants and children under 5 years of age

Position paper
Download:
Published: 2019 Author: SAGE

Interim Recommendations on Vaccination against Ebola Virus Disease (EVD)

Position paper
Download:
Published: 2019 Author: SAGE

What is the risk of other serious adverse events (non-dengue) in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE table
Download:
Published: 2018 Author: SAGE

What is the duration of protection/risk in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE table
Download:
Published: 2018 Author: SAGE

What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE table
Download:
Published: 2018 Author: SAGE

What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?

GRADE table
Download:
Published: 2018 Author: SAGE

What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?

GRADE table
Download:
Published: 2018 Author: SAGE

Should countries considering introduction of CYD-TDV to reduce the burden of dengue use a pre-vaccination screening or population seroprevalence based criteria?

Evidence to recommendation table
Download:
Published: 2018 Author: SAGE

Should CYD-TDV be recommended, over no vaccination, to immunocompetent individuals (≥9 years of age) in dengueendemic countries to mitigate the dengue burden of disease?

Evidence to recommendation table
Download:
Published: 2018 Author: SAGE